InvestorWire NewsRoom

Articles

Articles Category: Biotechnology
Thursday Jul 29, 2021 - 9:30 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Proprietary Imaging System Set to Advance Bladder Cancer Visualization

Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”)Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022 Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection Non-muscle-invasive bladder cancer (“NMIBC”) is a type of bladder cancer that has not…

Continue Reading

Thursday Jul 29, 2021 - 9:00 am

RYAH Group Inc. (CSE: RYAH) Globally Unlocking Data in the Complete Therapeutic Plant Lifecycle

Providing a holistic approach to therapeutic plant treatment by unlocking data from seed to consumptionRYAH Group is providing needed dosing devices globally to drive innovation and deliver cutting edge plant-based medical solutions globally With over 200k registered users, RYAH Group is one of the largest plant-based medicine databases in the world and regularly releases and shares valuable insights collected RYAH Group (CSE: RYAH), formerly RYAH Medtech,…

Continue Reading

Wednesday Jul 28, 2021 - 9:30 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Is ‘One to Watch’

MINDCURE’s proprietary digital therapeutics technology platform creates a high barrier to entry for any potential competitorsThe company maintains active partnerships with growing firms in AI, technology, and mental healthMINDCURE’s world-class scientific discovery team has decades of combined experience in researching and commercializing pharmaceutical grade drugsThe company has demonstrated a clear path to near-term revenues and boasts a strong financial position Mind Cure Health (CSE: MCUR)…

Continue Reading

Wednesday Jul 21, 2021 - 9:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Begin Patient Dosing in Berubicin Phase 2 Clinical Trial During Q3 2021, and Received Fast Track Designation from FDA

CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatmentsEnrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in adults is already underwayCNS Pharmaceuticals also secures additional funding of $4.7 million for pivotal study and operations into Q2 2022, adding to company’s significant accomplishments in short time CNS Pharmaceuticals (NASDAQ:…

Continue Reading

Tuesday Jul 20, 2021 - 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment

Former head of psychiatry products at FDA joins Cybin team.Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical…

Continue Reading

Monday Jul 19, 2021 - 11:22 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

XPhyto partners with AGORA t to grow its brand and overall market shareThe agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021AGORA is known for its online marketing, conferences, broadcasting and investor relations servicesIts clients include CardioComm Solutions, Good Life Networks, Northern…

Continue Reading

Monday Jul 19, 2021 - 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones.Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules.Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones,…

Continue Reading

Friday Jul 16, 2021 - 9:30 am

New Research Finds Neurological Damage in Patients Hospitalized with COVID-19; Brain Scientific (BRSF) Appears Poised to Offer Technology That Can Help Understand How COVID-19 Affects Brain

Scientific evidence is mounting that SARS-CoV-2 can cause neurological damage in patients hospitalized with the infection.A recent study that appeared in the journal JAMA Network Open finds five times increased mortality risk in patients hospitalized with COVID-19, citing encephalopathy as the most common neurological disease found in the clinical setting.As more research is needed to understand how COVID-19 affects the brain, Brain Scientific appears poised…

Continue Reading

Wednesday Jul 14, 2021 - 11:40 am

Brain Scientific Inc. (BRSF) Announces Merger Agreement With Piezo Motion to Expand Market Reach Into Fast-Growing Multi-Billion-Dollar Markets

BRSF is about to enter into a merger agreement to acquire Piezo Motion, a leading piezo motor technology developerPiezo Motion's technology will be deployed to leverage massive amounts of data that can be analyzed by artificial intelligence to assist medical professionals and researchers in recommending adequate precision treatmentsMerger expected to expand markets for both companies and their potential to deliver innovative technologies to high-growth segments…

Continue Reading

Tuesday Jul 13, 2021 - 9:57 am

BevCanna Enterprises Inc.’s (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) TRACE Line of Products Addresses Declining Minerals in Food Supply

Soil depletion causing mineral loss in food supplyBevCanna’s TRACE line of products address issue through proprietary plant-based formula rich in iron, magnesium, calcium, potassiumCompany recently signed distribution agreement to reach target markets in New York, Chicago, California BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, helps consumers address nutrient deficiencies with its TRACE line of…

Continue Reading

Monday Jul 12, 2021 - 12:31 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy

XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in BerlinThis marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategyThe lab tests are designed to offer reliable Covid-19 test results in under 25 minutesXPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023 For the week starting June 27, 2021, XPhyto Therapeutics…

Continue Reading

Thursday Jul 08, 2021 - 1:03 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Similar Strategy as Leading Cannabis-Derived Compound Pharmaceutical Company

Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compoundsTryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needsIt is one of only a handful of companies moving into Phase 2a…

Continue Reading

Wednesday Jul 07, 2021 - 10:26 am

Predictive Oncology Inc. (NASDAQ: POAI) Companies Build New Labs, Expand Services for New Drug Discoveries

Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customersWith its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to clinical trials, as well as manufacture proprietary media used in its chromatography kitsTumorGenesis will use its GMP lab to produce its proprietary media that tricks tumor cells into growing outside the…

Continue Reading

Tuesday Jul 06, 2021 - 9:15 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Featured in Stifel Report; Price Target Raised by C$12, Rated as Spec Buy

CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observedStifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distributionReport incorporates both CYB001 and CYB004 into valuation As Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to develop its multimolecule strategy,…

Continue Reading

Friday Jul 02, 2021 - 10:53 am

Predictive Oncology Inc. (NASDAQ: POAI) Stands Strong as Innovator, Leader in Precision Medicine

Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilitiesPOAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in the spacePredictive Oncology is strong standout in precision medicine Predictive Oncology (NASDAQ: POAI) has closed on its registered direct offering (https://ibn.fm/9buhx).The offering, which totaled $21.34 million, will be a boon for…

Continue Reading

Friday Jul 02, 2021 - 10:20 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit

Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and DevelopmentThe virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDTIt will focus on the psychedelics industry, showcasing the latest research and development within the sectorMr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline In…

Continue Reading

Wednesday Jun 30, 2021 - 2:06 pm

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule”The program, which started in early 2021, is slated for completion in late Q3 2021The first initial production batches were completed successfully, marking a significant milestone for the programMescaline will form a critical component in XPhyto’s psychedelic medicine program and work towards providing a foundation for its drug formulation and clinical validation…

Continue Reading

Friday Jun 25, 2021 - 2:17 pm

RYAH Group Inc. (CSE: RYAH) Cannabis Clinical Trials Improve Due to Dose-Measuring Devices

Cannabis is a chemically variable plant making its clinical trials problematic, before the creation of dose-measuring devicesRYAH Smart inhalers being used in one of the largest clinical studies of its kind focused on chronic pain Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating Regulating dose size in cannabis clinical trials has proven problematic from one test subject to another because cannabis is a chemically…

Continue Reading

Friday Jun 25, 2021 - 12:15 pm

Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder and Chief Medical Officer Shares Company’s Groundbreaking Work in New Book

Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial EpigeneticsThe book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovationThe book mainly covers craniofacial growth and developmental GeneticsIt also highlights the relationship between dentofacial anomalies and developmental deficiencies associated with downstream conditions such as Obstructive…

Continue Reading

Friday Jun 25, 2021 - 11:42 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs

In 2021, Tryp Therapeutics plans on expanding its academic collaborationsIt also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populationsTryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state, mainly through innovations in drug formulation and deliveryA primary objective…

Continue Reading

Thursday Jun 24, 2021 - 3:21 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Decision represents opportunity to help millions suffering from social, generalized anxiety disordersGlobal markets will reach an estimated $4 billion this year, with significant growth projected looking forwardWHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD,…

Continue Reading

Thursday Jun 24, 2021 - 2:15 pm

Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference

More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO ConferencePredictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021Companies leveraged different components of the conference to entertain new partnerships or customers Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like…

Continue Reading

Wednesday Jun 23, 2021 - 2:49 pm

Brain Scientific Inc. (BRSF) to Remain at the Forefront of Innovative Brain Diagnostics as the Sector Grows Across New Applications

As a leading innovator in brain diagnostics technology, BRSF appears well placed to spot and predict driving forces behind the industry's expected rapid growth BRSF's Marketing Director was featured in an article giving prediction about key trends driving brain monitoring space in 2021BRSF poised to remain at EEG forefront as exciting new opportunities lay ahead for this growing sector Recognized as a leading innovative player in…

Continue Reading

Monday Jun 21, 2021 - 12:08 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gains Inclusion on Russell 2000 Index as Brain Cancer Trial Enrollment Advances

Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating conditionCNS’s focus has been on developing a means of combating glioblastoma, a fatal, generally incurable class of brain cancers that are aggressive and recurrent amid current surgical and chemotherapy interventionsOne patient from the Phase…

Continue Reading

Monday Jun 21, 2021 - 11:40 am

Brain Scientific Inc. (BRSF) Pediatric-Specific Disposable EEG Cap Now Available

The company has developed and brought to market a pediatric NeuroCap EEG testing in pediatrics may help diagnose autism, one of the fastest-growing developmental disorders in the US, and provide better treatment for pediatric patients with epilepsy COVID-19 made the process challenging but the team completed their task on time despite no in-person contact and the process coming to a halt twice due to shutdowns Brain Scientific…

Continue Reading

Friday Jun 18, 2021 - 2:35 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Making Advances in Bladder Cancer Treatment Through Proprietary Imaging Technology

Company’s i/Blue Imaging System(TM) is expected to be completed in 2022The American Cancer Society estimates that 2021 will see 83,370 new cases of bladder cancer and approximately 17,200 deathsMore than half of the patients who underwent a cystoscopy to remove non-muscle-invasive bladder cancer will experience recurrence The bladder cancer market was valued at $3.43 billion in 2020, and is anticipated to reach $4.71 billion by 2028…

Continue Reading

Friday Jun 18, 2021 - 2:23 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reports First Quarter Financials; Anticipates Improved Patient Outcomes with Berubicin

Company expects reporting on interim analysis for the first 18 patients of a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients during the first half of 2022One patient from the first Berubicin trial has survived cancer-free for 14 years, while two patients saw tumor reduction of up to 80 percentCNS Pharmaceuticals reported a net loss of $3.6 million, attributed to increased personnel,…

Continue Reading

Friday Jun 18, 2021 - 1:48 pm

RYAH Group Inc. (CSE: RYAH) Completes First Shipment of SMART Inhalers to UK Clinical Trial

The first shipment of SMART inhalers, 10,000 cartridges and QR codes arrived in the UK for the clinic's pilot runDue to the large scale of the clinical trial, RYAH developed a custom software solution for the clinicIn the UK the medical cannabis market is expected to reach $1.3 billion by 2024, and 1% of the population could be medical cannabis patients by 2028 RYAH Group…

Continue Reading

Thursday Jun 17, 2021 - 10:53 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces First-Ever Trial to Treat COVID-19 Frontline Clinicians, Unveils EMBARK Model

The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stressEMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicineCybin considers it an honor, duty to support healing processes of doctors, nurses and healthcare professionals, says CEO In the first-ever study of its kind, Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic…

Continue Reading

Thursday Jun 17, 2021 - 9:00 am

Brain Scientific Inc. (BRSF) Poised to Contribute to Mental Health Research; Provides Technology to Map Brain Response to Psychedelic Treatment

BRSF has partnered with Ehave to conduct research connected to biochemical biomarkers concerning psychedelic drug administrationPsychedelic drugs show promise in treating neurological disorders, including chronic pain, depression, and PTSD, but more research is neededBRSF's E-Tattoo is poised to bring benefits of biomarkers to neurological and psychiatric research; allows monitoring of patient's brain activity in a non-intrusive way Brain Scientific (OTCQB: BRSF) has partnered with Ehave,…

Continue Reading

Wednesday Jun 16, 2021 - 10:38 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference

Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needsThe company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare ConferenceTryp’s synthetic psychedelic drug candidate will be further developed in an upcoming phase 2a clinical study in partnership with pediatric eating…

Continue Reading

Tuesday Jun 15, 2021 - 1:14 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commences Sale of Rapid COVID-19 RT-PCR Test Kits in Germany Amid Potential Surge in Demand

XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the marketThe announcement comes as Germany reopens, meaning XPhyto is likely to benefit from a raft of regulatory requirements instituted by the government,…

Continue Reading

Tuesday Jun 15, 2021 - 9:15 am

Brain Scientific Inc. (BRSF) Tech to be Used in a Ketamine Clinical Study for Mental Health Care

Ehave announced it will utilize BRSF's tech in an upcoming ketamine clinical studyBRSF's tech will make it possible to correlate biomarkers for the identification of chronic pain, depression, PTSD, bipolar disorder, and more. The data from this clinical trial has the potential to provide longitudinal insights that can link brain analysis and psychedelics Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is on a mission…

Continue Reading

Tuesday Jun 15, 2021 - 9:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Expands Sales into Public Sector with BC Liquor Distribution Board Purchase

PULL secures edible cannabis gummies order from British Columbia Liquor Distribution BranchPULL’s cannabis gummies produced in blister packs using proprietary manufacturing system licensed from US-based Taste-T, LLC SKUs include 10 mg THC options in Fire Burst, Strawberry, and Mango flavors, three additional non-THC SKUs currently in developmentGlobal CBD gummies market estimated at $1.6 billion in 2020, 30.7% CAGR from 2021 to 2028   Pure Extracts Technologies (CSE:…

Continue Reading

Monday Jun 14, 2021 - 9:58 am

DGE’s 2nd Medical Writing Innovation Strategies Conference for Life Sciences

Date: June 29-30, 2021Online Livestream Event Biopharma medical writing and communications professionals are invited are invited to attend DGE’s 2nd Medical Writing Innovation Strategies Conference for Life Sciences live streaming on June 29-30, 2021. The event will offer useful tips and guide medical professionals to learn innovative skills for filtering technical information that is effectively communicated for engagement. These power-packed sessions will assist medical writers…

Continue Reading

Monday Jun 14, 2021 - 9:00 am

Healthy Extracts Inc. (HYEX) Stands Distinct in the Development, Provision of Highest-Quality Supplements with Proven Health Benefits

HYEX’s portfolio of wholly owned subsidiaries currently comprises BergametNA and Ultimate Brain NutrientsBergametNA, whose products target cardiovascular and immune health, sources its formulations from the Citrus Bergamot SuperFruit(TM)The bergamot fruit is richly packed with polyphenolic flavanones, which are known to decrease bad cholesterol, triglyceride, and glucose, as well as increase the good cholesterolBergaMet only uses the highest concentration of polyphenolic flavanones (“BPF”) as the higher…

Continue Reading

Friday Jun 11, 2021 - 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Kernel Flow, Ketamine Feasibility Study

Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamicsCybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trialsKetamine is a dissociative injected anesthetic that blocks sensory perception Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the…

Continue Reading

Friday Jun 11, 2021 - 9:00 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) on Course for Private Demonstrations of the i/Blue Imaging System(TM) at the American Urological Association Annual Conference in September

Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDABladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder cancer treatment and managementImagin Medical plans to complete its proprietary i/Blue…

Continue Reading

Thursday Jun 10, 2021 - 10:44 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference

Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development programTryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics Psychedelics have increasingly drawn the attention of different players and…

Continue Reading

Thursday Jun 10, 2021 - 9:51 am

Brain Scientific Inc. (BRSF) Poised to Offer Brain Monitoring Solution as Research Shows Neurological Findings in COVID-19 Long-Haulers

Most extensive research to date reports significant neurological problems in patients who suffered from so-called long-haul COVID-19Neurological issues range from mild to more severe such as cognitive impairment, which affects around 20% of these patientsBRSF appears poised to be part of the solution as long-haulers need monitoring so that doctors can assess if they have neurological disorders The neurological and psychiatric aftermath of COVID-19 has…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).